Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00557401 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD
A Phase 2 study, sponsored by XenoPort.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT00557401 is a Phase 2 study that has completed, run by XenoPort. The registered enrollment target is 156 participants.
The verdict
NCT00557401, a Phase 2 study, has completed, sponsored by XenoPort.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with symptomatic GERD
Interventions
- DRUG Placebo
- DRUG XP19986 SR3, 20 mg QD
- DRUG XP19986 SR3, 40 mg QD
- DRUG XP19986 SR3, 60 mg QD
- DRUG XP19986 SR3, 30 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00557401
The ClinicalTrials.gov registry entry for NCT00557401 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is XenoPort, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00557401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00557401 about?
NCT00557401 is a clinical study titled "An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD". To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with symptomatic GERD
What is the current status of trial NCT00557401?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2007-11. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00557401?
The interventions under investigation include: Placebo (DRUG), XP19986 SR3, 20 mg QD (DRUG), XP19986 SR3, 40 mg QD (DRUG), XP19986 SR3, 60 mg QD (DRUG), XP19986 SR3, 30 mg BID (DRUG).
Who is sponsoring clinical trial NCT00557401?
This trial is sponsored by XenoPort, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.